Survival by treatment type and site. Kaplan-Meier curves of (A) PFS and (B) OS for 3 most common chemotherapy regimens. Three-year PFS rates for CODOX-M/IVAC vs hyperCVAD/MA vs DA-EPOCH were 71% (95% CI, 64-77) vs 67% (95% CI, 60-73) vs 62% (95% CI, 55-69), respectively, stratified P = .22; corresponding 3-year OS rates were 77% (95% CI, 70-83) vs 70% (95% CI, 63-76) vs 69% (95% CI 61-75), respectively, stratified P = .39. Kaplan-Meier curves of (C) PFS and (D) OS based on receipt of rituximab and site of administration. Three-year PFS rates for patients who received rituximab compared with patients who did not receive rituximab as a component of initial therapy were 67% (95% CI, 63-71) vs 38% (95% CI, 26-50), respectively, stratified P < .001, with 3-year OS rates of 72% (95% CI, 68-76) vs 44% (95% CI, 32-56), respectively, stratified P < .001. Three-year PFS rates for patients who received rituximab outpatient vs inpatient were 69% (95% CI, 62-76) vs 66% (95% CI, 61-71), stratified P = .24; the 3-year OS rates were 75% (95% CI, 68-81) vs 71% (95% CI, 66-75), respectively, stratified P = .37. Kaplan-Meier curves of (E) PFS and (F) OS based on treatment location. Three-year PFS rates for patients treated in an academic center vs community oncology center were 67% (95% CI, 63-71) vs 46% (95% CI, 34-57), respectively, stratified P = .006; 3-year OS rates were 72% (95% CI, 68-75) vs 53% (95% CI, 41-64), respectively, stratified P = .010. Stratification factors for log-rank tests were age ≥ 40 years, LDH > 3× ULN, ECOG performance status 2 to 4, and CNS involvement.